Clinical considerations and pathophysiological associations among obesity, weight loss, heart failure, and hypertension.

IF 2 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Opinion in Cardiology Pub Date : 2023-09-01 DOI:10.1097/HCO.0000000000001069

Maria Irene Barillas-Lara, Christian C Faaborg-Andersen, Raymundo A Quintana, Juan Francisco Loro-Ferrer, Stacy A Mandras, Adrian daSilva-deAbreu

{"title":"Clinical considerations and pathophysiological associations among obesity, weight loss, heart failure, and hypertension.","authors":"Maria Irene Barillas-Lara, Christian C Faaborg-Andersen, Raymundo A Quintana, Juan Francisco Loro-Ferrer, Stacy A Mandras, Adrian daSilva-deAbreu","doi":"10.1097/HCO.0000000000001069","DOIUrl":null,"url":null,"abstract":"Purpose of review: To describe the relationship between three pandemics: hypertension, obesity, and heart failure. From pathophysiology to treatment, understanding how these disease entities are linked can lead to breakthroughs in their prevention and treatment. The relevance of this review lies in its discussion of novel pharmacological and surgical treatment strategies for obesity and hypertension, and their role in the prevention and treatment of heart failure.Recent findings: Novel medications such as GLP-1 agonists have demonstrated sustained weight loss in patients with obesity, and concurrent improvements in their cardiometabolic profile, and possibly also reductions in hypertension-related comorbidities including heart failure. Surgical therapies including laparoscopic bariatric surgery represent an important treatment strategy in obese patients, and recent studies describe their use even in patients with advanced heart failure, including those with ventricular assist devices.Summary: These developments have deep implications on our efforts to understand, mitigate, and ultimately prevent the three pandemics, and offer promising improvements to quality of life, survival, and the cost burden of these diseases.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/HCO.0000000000001069","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose of review: To describe the relationship between three pandemics: hypertension, obesity, and heart failure. From pathophysiology to treatment, understanding how these disease entities are linked can lead to breakthroughs in their prevention and treatment. The relevance of this review lies in its discussion of novel pharmacological and surgical treatment strategies for obesity and hypertension, and their role in the prevention and treatment of heart failure.

Recent findings: Novel medications such as GLP-1 agonists have demonstrated sustained weight loss in patients with obesity, and concurrent improvements in their cardiometabolic profile, and possibly also reductions in hypertension-related comorbidities including heart failure. Surgical therapies including laparoscopic bariatric surgery represent an important treatment strategy in obese patients, and recent studies describe their use even in patients with advanced heart failure, including those with ventricular assist devices.

Summary: These developments have deep implications on our efforts to understand, mitigate, and ultimately prevent the three pandemics, and offer promising improvements to quality of life, survival, and the cost burden of these diseases.

查看原文本刊更多论文

肥胖、体重减轻、心力衰竭和高血压之间的临床考虑和病理生理关联。

综述的目的:描述三种流行病:高血压、肥胖和心力衰竭之间的关系。从病理生理学到治疗，了解这些疾病实体是如何联系在一起的，可以在预防和治疗方面取得突破。这篇综述的相关性在于它讨论了肥胖和高血压的新的药物和手术治疗策略，以及它们在预防和治疗心力衰竭中的作用。最近的发现:新型药物如GLP-1激动剂已经证明肥胖患者的体重持续下降，同时改善他们的心脏代谢状况，并且可能还减少高血压相关的合并症，包括心力衰竭。包括腹腔镜减肥手术在内的外科治疗是肥胖患者的重要治疗策略，最近的研究甚至描述了他们在晚期心力衰竭患者中的应用，包括那些有心室辅助装置的患者。总结:这些发展对我们理解、减轻并最终预防这三种流行病的努力具有深远的影响，并有望改善这些疾病的生活质量、生存率和成本负担。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Cardiology 医学-心血管系统

CiteScore

4.20

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Cardiology is a bimonthly publication offering a unique and wide ranging perspective on the key developments in the field. Each issue features hand-picked review articles from our team of expert editors. With fourteen disciplines published across the year – including arrhythmias, molecular genetics, HDL cholesterol and clinical trials – every issue also contains annotated reference detailing the merits of the most important papers.